A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
There is no agreement on a single treatment strategy for patients with hepatocellular carcinoma (HCC). Selection of treatment is complex due to several factors, including:
Underlying liver function.
Extent and location of the tumor.
General condition of the patient.
Several treatments for HCC are associated with long-term survival, including surgical resection, liver transplant, and ablation. There are no large, robust, randomized studies that compare treatments considered effective for early-stage disease, nor are there studies comparing these treatments with best supportive care. Often, patients with HCC are evaluated by a multidisciplinary team that includes hepatologists, radiologists, interventional radiologists, radiation oncologists, transplant surgeons, surgical oncologists, pathologists, and medical oncologists.
Best survivals are achieved when the HCC can be removed either by surgical resection or liver transplant. Surgical resection is usually performed in patients with localized HCC and enough functional hepatic reserve.
For patients with decompensated cirrhosis and a solitary lesion (<5 cm) or early multifocal disease (≤3 lesions, ≤3 cm in diameter), the best option is liver transplant.[1] However, the limited availability of liver donors restricts the use of this approach.
Sources: 1
Transarterial chemoembolization, multikinase inhibitors, and immunotherapy are noncurative treatments for HCC that improve survival.[2-4]
Table 5 shows the standard treatment options for HCC.
| Stage | Treatment Options |
|---|---|
| Localized | Surveillance |
| Surgical resection | |
| Liver transplant | |
| Ablation | |
| Radiation therapy | |
| Locally advanced or metastatic | Transarterial embolization and transcatheter arterial chemoembolization in patients with nonmetastatic disease |
| First-line systemic therapy | |
| Second-line systemic therapy | |
| Radiation therapy | |
| Recurrent (liver-limited disease without vascular involvement) | Liver transplant |
| Surgical resection | |
| Ablation | |
| Radiation therapy | |
| Recurrent (extrahepatic disease or vascular involvement) | Palliative therapy |
Sources: Surveillance · Surgical resection · Liver transplant · Ablation · Radiation therapy · Transarterial embolization and transcatheter arterial chemoembolization in patients with nonmetastatic disease · First-line systemic therapy · Second-line systemic therapy · Radiation therapy · Liver transplant · Surgical resection · Ablation · Radiation therapy · Palliative therapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
About 30% of hepatocellular carcinoma (HCC) cases present as localized disease, with a solitary mass in part of the liver or as a limited number of tumors (≤3 lesions, ≤3 cm in diameter) without major vascular invasion.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for localized primary liver cancer include:
Surveillance.
Sources: Surveillance
Surgical resection.
Sources: Surgical resection
Liver transplant.
Sources: Liver transplant
Ablation.
Sources: Ablation
Radiation therapy.
Sources: Radiation therapy
Resection and transplant achieve the best outcomes in well-selected candidates, and are usually considered the first option for curative intent.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Surveillance is an option for patients at high risk of HCC with lesions smaller than 1 cm detected during screening.[1][Level of evidence C1] Close follow-up at 3-month intervals is a common surveillance strategy, using the same technique that first documented the presence of the lesions.
Sources: 1 · Level of evidence C1
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Surgery is the mainstay of HCC treatment.
Preoperative assessment includes three-phase helical computed tomography, magnetic resonance imaging, or both to determine the presence of an extension of a tumor across interlobar planes and potential involvement of the hepatic hilus, hepatic veins, and inferior vena cava. Tumors can be resected only if enough liver parenchyma can be spared with adequate vascular and biliary inflow and outflow. Patients with well-compensated cirrhosis can generally tolerate resection of up to 50% of their liver parenchyma.
Surgical resection can be considered for patients who meet the following criteria:
A solitary mass.
Good performance status.
Normal or minimally abnormal liver function tests.
No evidence of portal hypertension.
No evidence of cirrhosis beyond Child-Pugh class A.
After considering the location and number of tumors and the patient's hepatic function, only 5% to 10% of patients with liver cancer will prove to have localized disease amenable to resection.[2-6]
The principles of surgical resection involve obtaining a clear margin around the tumor, which may require any of the following procedures:
Segmental resection.
Hormone-lymphatic lobectomy.
Extended lobectomy.
The 5-year overall survival (OS) rate after curative resection ranges between 27% and 70% and depends on tumor stage and underlying liver function.[2-6]
In patients with limited multifocal disease, hepatic resection is controversial.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Liver transplant is a potentially curative therapy for HCC and has the benefit of treating the underlying cirrhosis, but the scarcity of organ donors limits the availability of this treatment modality.[2]
Sources: 2
According to the Milan criteria, patients with a single HCC lesion smaller than 5 cm, or 2 to 3 lesions smaller than 3 cm are eligible for liver transplant. Expansion of the accepted transplant criteria for HCC is not supported by consistent data. Liver transplant is considered if resection is precluded because of multiple small tumor lesions (≤3 lesions, each ≤3 cm), or impaired liver function (Child-Pugh class B and class C). In patients who meet the criteria, transplant is associated with a 5-year OS rate of approximately 70%.[7][Level of evidence C1]
Sources: 7 · Level of evidence C1
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
When tumor excision, either by transplant or resection, is not feasible or advisable, ablation may be used if the tumor can be accessed percutaneously or, if necessary, through minimally invasive or open surgery. Ablation may be particularly useful for patients with early-stage HCC that is centrally located in the liver and cannot be surgically removed without excessive sacrifice of functional parenchyma.
Ablation can be achieved in the following ways:
Change in temperature (e.g., radiofrequency ablation [RFA], microwave, or cryoablation).
Exposure to a chemical substance (e.g., percutaneous ethanol injection [PEI]).
Direct damage of the cellular membrane (definitive electroporation).
With ablation, a margin of normal liver around the tumor can be considered. Ablation is relatively contraindicated for lesions near bile ducts, the diaphragm, or other intra-abdominal organs that might be injured during the procedure. Furthermore, when tumors are located adjacent to major vessels, the blood flow in the vessels may keep thermal ablation techniques, such as RFA, from reaching optimal temperatures. This is known as the heat-sink effect, which may preclude complete tumor necrosis.
RFA achieves best results in patients with tumors smaller than 3 cm. In this subpopulation, 5-year OS rates may be as high as 59%, and the recurrence-free survival rates may not differ significantly from treatment with hepatic resection.[8,9] Local control success progressively diminishes as the tumor size increases beyond 3 cm.
PEI yields good results in patients with Child-Pugh class A cirrhosis and a single tumor smaller than 3 cm in diameter. In those cases, the 5-year OS rate can be as high as 40% to 59%.[10,11][Level of evidence C2]
Sources: 10 · 11 · Level of evidence C2
In the few randomized controlled trials that included patients with Child-Pugh class A cirrhosis, RFA proved superior to PEI in rates of complete response and local recurrences. Some of those studies have also shown improved OS with RFA. Furthermore, RFA requires fewer treatment sessions than PEI to achieve comparable outcomes.[12-15]
Of note, RFA may have higher complication rates than PEI,[13] but both techniques are associated with lower complication rates than excision procedures. RFA is a well-established technique in the treatment of HCC.
Sources: 13
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Radiation therapy can be delivered with curative or palliative intent for patients with primary liver cancer. One form of radiation, stereotactic body radiation therapy (SBRT), treats patients with a small number of fractions of precise, image-guided radiation therapy at a high biologically equivalent dose. Numerous retrospective studies have shown excellent local control for patients with HCC who receive SBRT (local control rates ranging from 70%–95% at 2 years for smaller HCCs).
Evidence (curative radiation therapy):
The phase III NRG/RTOG 1112 study (NCT01730937) evaluated sorafenib alone or SBRT followed by sorafenib in patients with HCC. Patients were included if they had Child-Pugh class A, Barcelona Clinic Liver Cancer stage B or C, new or recurrent HCC. Patients also had five or fewer lesions, a tumor sum measuring 20 cm or less, and distant metastases measuring 3 cm or less. A total of 177 patients were randomly assigned (92 to sorafenib alone, 85 to SBRT followed by sorafenib). The primary end point was OS.[16][Level of evidence B1]
Sources: NRG/RTOG 1112 · 16 · Level of evidence B1
The phase III NRG/RTOG 1112 study (NCT01730937) evaluated sorafenib alone or SBRT followed by sorafenib in patients with HCC. Patients were included if they had Child-Pugh class A, Barcelona Clinic Liver Cancer stage B or C, new or recurrent HCC. Patients also had five or fewer lesions, a tumor sum measuring 20 cm or less, and distant metastases measuring 3 cm or less. A total of 177 patients were randomly assigned (92 to sorafenib alone, 85 to SBRT followed by sorafenib). The primary end point was OS.[16][Level of evidence B1]
The median OS was 12.3 months for the sorafenib-alone group and 15.8 months for the SBRT-plus-sorafenib group (hazard ratio [HR], 0.77; one-sided P = .0554). This was not statistically significant.
Grade 3 or higher adverse events were not significantly different between the two groups: 42% for the sorafenib-alone group and 47% for the SBRT-plus-sorafenib group (P = .52).
There were three grade 5 adverse events: one hepatic failure and one death not otherwise specified in the sorafenib-alone group and one grade 5 lung infection in the SBRT-plus-sorafenib group.
Based on these results, SBRT is a standard of care treatment with curative intent for HCC. It can also be used to provide local control before liver transplant.
Evidence (radiation therapy for palliation):
The Canadian Cancer Trials Group HE.1 trial (NCT02511522), a phase III study published in abstract form, included 66 patients with HCC. Patients were randomly assigned to receive either best supportive care alone or palliative radiation therapy to the liver (8 Gy in one fraction). Patients had end-stage disease unsuitable for local, regional, or systemic therapies. Patients also had to be more than 4 weeks from receiving chemotherapy or transcatheter arterial chemoembolization, more than 2 weeks from receiving targeted therapy or immunotherapy, and not planning any systemic therapy. The primary outcome of the study was the proportion of patients who reported an improvement of at least two points from baseline on the Brief Pain Inventory when asked to rate their liver cancer pain "intensity at worst." A secondary end point included 3-month OS.[17][Level of evidence B3]
Sources: HE.1 · 17 · Level of evidence B3
The Canadian Cancer Trials Group HE.1 trial (NCT02511522), a phase III study published in abstract form, included 66 patients with HCC. Patients were randomly assigned to receive either best supportive care alone or palliative radiation therapy to the liver (8 Gy in one fraction). Patients had end-stage disease unsuitable for local, regional, or systemic therapies. Patients also had to be more than 4 weeks from receiving chemotherapy or transcatheter arterial chemoembolization, more than 2 weeks from receiving targeted therapy or immunotherapy, and not planning any systemic therapy. The primary outcome of the study was the proportion of patients who reported an improvement of at least two points from baseline on the Brief Pain Inventory when asked to rate their liver cancer pain "intensity at worst." A secondary end point included 3-month OS.[17][Level of evidence B3]
A significant improvement in the “worst” pain score from baseline to 1 month was seen in 67% of patients who received radiation therapy and 22% of patients who received best supportive care.
Although radiation therapy has not been historically used in this patient population, this study showed no decrease in OS for patients who received radiation. The 3-month OS rate was 51% for patients who received radiation therapy and 33% for patients who received best supportive care alone (P = .07), despite the study including patients with Child-Pugh class A, B, and C cirrhosis.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Treatment options for locally advanced or metastatic primary liver cancer not amenable to surgical or locoregional interventions include:
Transarterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) in patients with nonmetastatic disease.
First-line systemic therapy.
Sources: First-line systemic therapy.
First-line systemic therapy.
Combination immunotherapy and targeted therapy.
First-line systemic therapy. › Combination immunotherapy and targeted therapy.
Atezolizumab and bevacizumab.
Sources: Atezolizumab and bevacizumab
Atezolizumab and cabozantinib.
Sources: Atezolizumab and cabozantinib
First-line systemic therapy.
Combination immunotherapy alone.
Sources: Combination immunotherapy alone
First-line systemic therapy. › Combination immunotherapy alone.
Doublet immune checkpoint inhibitors.
Sources: Doublet immune checkpoint inhibitors
Single-agent immune checkpoint inhibitors.
First-line systemic therapy.
Targeted therapy (multikinase inhibitors).
First-line systemic therapy. › Targeted therapy (multikinase inhibitors).
Lenvatinib.
Sources: Lenvatinib
Sorafenib.
Sources: Sorafenib
Second-line systemic therapy.
Sources: Second-line systemic therapy
Second-line systemic therapy.
Targeted therapy (multikinase inhibitors).
Second-line systemic therapy. › Targeted therapy (multikinase inhibitors).
Regorafenib.
Sources: Regorafenib
Cabozantinib.
Sources: Cabozantinib
Ramucirumab.
Sources: Ramucirumab
Second-line systemic therapy.
Combination immunotherapy and immunotherapy alone.
Second-line systemic therapy. › Combination immunotherapy and immunotherapy alone.
Pembrolizumab.
Sources: Pembrolizumab
Nivolumab and ipilimumab.
Sources: Nivolumab and ipilimumab
Nivolumab.
Sources: Nivolumab
Radiation therapy.
Sources: Radiation therapy
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
TAE is the most widely used primary treatment for hepatocellular carcinoma (HCC) not amenable to curative treatment by excision or ablation. Most of the blood supply to the normal liver parenchyma comes from the portal vein, whereas blood flow to the tumor comes mainly from the hepatic artery. Furthermore, HCC tumors are generally hypervascular compared with the surrounding normal parenchyma. The obstruction of the arterial branch(es) feeding the tumor may reduce the blood flow to the tumor and result in tumor ischemia and necrosis.
Embolization agents, such as microspheres and particles, may also be administered along with concentrated doses of chemotherapeutic agents (generally doxorubicin or cisplatin) mixed with lipiodol or other emulsifying agents during chemoembolization, arterial chemoembolization (usually via percutaneous access), and TACE. TAE-TACE is considered for patients with HCC not amenable to surgery or percutaneous ablation in the absence of extrahepatic disease.
In patients with cirrhosis, any interference with arterial blood supply may be associated with significant morbidity and is relatively contraindicated in the presence of portal hypertension, portal vein thrombosis, or clinical jaundice. In patients with liver decompensation, TAE-TACE could increase the risk of liver failure.
A number of randomized controlled trials have compared TAE and TACE with supportive care.[1] Those trials have been heterogeneous in terms of patient baseline demographics and treatment. The survival advantage of TAE-TACE over supportive care has been demonstrated by two trials.[2,3] No standardized approach for TAE has been determined (e.g., embolizing agent, chemotherapy agent and dose, and treatment schedule). However, a meta-analysis has shown that TAE-TACE improves survival more than supportive treatment.[1]
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Historically, sorafenib (a multikinase inhibitor) has been the standard of care for patients with advanced HCC and intact liver function (Child-Pugh class A) who were not candidates for locoregional therapy. This standard was based on the results of the SHARP trial, which showed improved OS for patients who received sorafenib compared with placebo (10.7 vs. 7.9 months; hazard ratio [HR], 0.69; P < .001). However, treatment-related adverse events may make adherence to sorafenib regimens difficult, especially in a population with concurrent liver disease. Since 2018, additional drugs and drug combinations, including atezolizumab-bevacizumab and durvalumab-tremelimumab, have resulted in improved OS when compared with sorafenib, resulting in U.S. Food and Drug Administration (FDA) approval. Other regimens have demonstrated noninferiority when compared with sorafenib, including lenvatinib (a multikinase inhibitor) and immunotherapy monotherapy. In choosing first-line therapy, survival data, response rates, bleeding risk (i.e., active varices), and the likelihood of tolerating individual therapies should be considered.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The combination of atezolizumab (an anti–PD-L1 inhibitor) and bevacizumab (a VEGF inhibitor) has produced improved OS compared with sorafenib. The FDA approved this combination for patients with advanced HCC and Child-Pugh class A liver function. Additional combination therapies are being evaluated.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (atezolizumab and bevacizumab):
The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]
Sources: Imbrave150 · 9
The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]
The OS was 19.2 months (95% confidence interval [CI], 17.0–23.7) in the atezolizumab-bevacizumab arm and 13.4 months (95% CI, 11.4–16.9) in the sorafenib arm (HR, 0.66; 95% CI, 0.52–0.85; P < .001).[9][Level of evidence A1]
Sources: 9 · Level of evidence A1
The objective response rates were 30% (95% CI, 25%–35%) in the atezolizumab-bevacizumab arm and 11% (95% CI, 7%–17%) in the sorafenib arm.
In subgroup-analyses, the OS benefit was generally consistent, but with less effect in those with a nonviral etiology of HCC.
Grade 3 or higher treatment-related adverse events occurred in 63% of patients in the atezolizumab-bevacizumab arm and 57% of patients in the sorafenib arm.[10]
Sources: 10
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (atezolizumab and cabozantinib):
The global, open-label, phase III COSMIC-312 trial (NCT03755791) included 837 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1:1 ratio to receive either cabozantinib (40 mg PO daily) with atezolizumab (1,200 mg IV every 3 weeks), sorafenib (400 mg PO bid), or cabozantinib (60 mg daily). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with gastric or esophageal varices with active bleeding in the 6 months before enrollment.[11]
Sources: COSMIC-312 · 11
The global, open-label, phase III COSMIC-312 trial (NCT03755791) included 837 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1:1 ratio to receive either cabozantinib (40 mg PO daily) with atezolizumab (1,200 mg IV every 3 weeks), sorafenib (400 mg PO bid), or cabozantinib (60 mg daily). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with gastric or esophageal varices with active bleeding in the 6 months before enrollment.[11]
The first primary end point explored median progression-free survival (PFS) in the first 372 patients randomly assigned to combination therapy or sorafenib. Among those patients, the median PFS was 6.8 months (99% CI, 5.6–8.3) in the cabozantinib-atezolizumab arm and 4.2 months (95% CI, 2.8–7.0) in the sorafenib arm (HR, 0.63; 99% CI, 0.44–0.91; P = .0012).[11][Level of evidence B1]
Sources: 11 · Level of evidence B1
However, at interim analysis, the OS was similar, at 15.4 months (96% CI, 13.7–17.7) for patients in the cabozantinib-atezolizumab combination arm (n = 432) and 15.5 months (12.1–not estimable) for patients in the sorafenib arm (n = 217) (HR, 0.90; 96% CI, 0.69–1.18; P = .44).
At interim analysis, the PFS was 5.8 months (99% CI, 5.4–8.2) in the cabozantinib arm and 4.3 months (99% CI, 2.9–6.1) in the sorafenib arm (HR, 0.71; 99% CI, 0.51–1.01; P = .011).
Objective response rates were 11% (8.1%–14.2%) in the cabozantinib-atezolizumab arm, 4% (1.6%–7.1%) in the sorafenib arm, and 6% (3.3%–10.9%) in the cabozantinib arm.
Grade 3 or higher treatment-related adverse events occurred in 76% of patients in the cabozantinib-atezolizumab arm, 57% of patients in the sorafenib arm, and 76% of patients in the cabozantinib arm.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
While single-agent immune checkpoint inhibitors have not demonstrated improved survival benefit over tyrosine kinase inhibitors (TKIs), dual immune checkpoint inhibitors have shown improved objective response rates and OS, but with increased autoimmune side effects. Optimal dosing of combination therapies is being evaluated. In 2022, based on the data below, the FDA approved the combination of a single priming dose of tremelimumab with durvalumab every 4 weeks.
Sources: below
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (doublet immune checkpoint inhibitors):
The global, open-label, phase III HIMALAYA trial (NCT03298451) included 1,171 patients with unresectable HCC and Child-Pugh class A liver disease who had not received prior systemic treatment. Patients were randomly assigned in a 1:1:1 ratio to receive STRIDE (a single dose of tremelimumab 300 mg IV) with durvalumab (1,500 mg IV) every 4 weeks, durvalumab monotherapy (1,500 mg IV every 4 weeks), or sorafenib (500 mg PO bid).[12]
The global, open-label, phase III HIMALAYA trial (NCT03298451) included 1,171 patients with unresectable HCC and Child-Pugh class A liver disease who had not received prior systemic treatment. Patients were randomly assigned in a 1:1:1 ratio to receive STRIDE (a single dose of tremelimumab 300 mg IV) with durvalumab (1,500 mg IV) every 4 weeks, durvalumab monotherapy (1,500 mg IV every 4 weeks), or sorafenib (500 mg PO bid).[12]
The median OS was 16.43 months (95% CI, 14.16–19.58) in the combination tremelimumab-durvalumab arm and 13.77 months (95% CI, 12.25–16.13) in the sorafenib arm (HR, 0.78; 96.02% CI, 0.65–0.93; P = .0035).[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
The objective response rate was 20.1% for patients who received STRIDE and 5.1% for patients who received sorafenib.
Grade 3 or higher treatment-related adverse events occurred in 50.5% of patients who received combination tremelimumab and durvalumab and 52.4% of patients who received sorafenib.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (single-agent immune checkpoint inhibitors):
The HIMALAYA trial discussed above analyzed end points for patients randomly assigned to the durvalumab monotherapy arm (n = 389) or the sorafenib monotherapy arm (n = 389).[12]
The HIMALAYA trial discussed above analyzed end points for patients randomly assigned to the durvalumab monotherapy arm (n = 389) or the sorafenib monotherapy arm (n = 389).[12]
The median OS for patients who received durvalumab monotherapy (16.56 months; 95% CI, 14.06–19.12) was noninferior to the median OS for patients who received sorafenib monotherapy (13.77 months; 95% CI, 12.25–16.13) (HR, 0.86; 95.67% CI, 0.73–1.03; noninferiority margin, 1.08).[12][Level of evidence B3]
Sources: 12 · Level of evidence B3
The objective response rate was 8.2% in the durvalumab arm and 4.9% in the sorafenib arm.
Grade 3 or higher treatment-related adverse events occurred in 37.1% of patients who received durvalumab.
The randomized, open-label, phase III CheckMate 459 trial (NCT02576509) included 743 patients with Child-Pugh class A liver disease and unresectable HCC who were naïve to systemic treatment. Patients were randomly assigned in a 1:1 ratio to receive either nivolumab (n = 371) or sorafenib (n = 372).[13]
Sources: CheckMate 459 · 13
The randomized, open-label, phase III CheckMate 459 trial (NCT02576509) included 743 patients with Child-Pugh class A liver disease and unresectable HCC who were naïve to systemic treatment. Patients were randomly assigned in a 1:1 ratio to receive either nivolumab (n = 371) or sorafenib (n = 372).[13]
The median OS was 16.4 months (95% CI, 13.9–18.4) in the nivolumab arm and 14.7 months (95% CI, 11.9–17.2) in the sorafenib arm (HR, 0.85; 95% CI, 0.72–1.02; P = .075).[13][Level of evidence B3]
Sources: 13 · Level of evidence B3
The objective response rate was 15% (95% CI, 12%–19%) in the nivolumab arm and 7% (95% CI, 5%–10%) in the sorafenib arm.
Grade 3 or higher treatment-related adverse events occurred in 23% of patients who received nivolumab and 49% of patients who received sorafenib.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
The FDA has approved two oral multikinase inhibitors, lenvatinib and sorafenib, for first-line treatment of patients with advanced HCC with well-compensated liver function who are not amenable to local therapies.
There are limited data on treatment options for patients with decompensated liver function.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (lenvatinib):
An international, open-label, phase III, noninferiority trial (E7080-G000-304 [NCT01761266]) that included patients from 20 countries in Asia, Europe, and North America enrolled 954 patients with advanced HCC and Child-Pugh class A disease. Patients were randomly assigned in a 1:1 ratio to receive either lenvatinib (12 mg qd for body weight >60 kg or 8 mg for body weight <60 kg) or sorafenib (400 mg bid in 28-day cycles).[14] Patients with more than 50% liver involvement and portal vein invasion were excluded.
Sources: E7080-G000-304 · 14
An international, open-label, phase III, noninferiority trial (E7080-G000-304 [NCT01761266]) that included patients from 20 countries in Asia, Europe, and North America enrolled 954 patients with advanced HCC and Child-Pugh class A disease. Patients were randomly assigned in a 1:1 ratio to receive either lenvatinib (12 mg qd for body weight >60 kg or 8 mg for body weight <60 kg) or sorafenib (400 mg bid in 28-day cycles).[14] Patients with more than 50% liver involvement and portal vein invasion were excluded.
The median OS was 13.6 months, which reached noninferiority, for patients who received lenvatinib and 12.3 months for patients who received sorafenib (HR, 0.92; 95% CI, 0.79–1.06).[14][Level of evidence B1]
Sources: 14 · Level of evidence B1
The median PFS was 7.4 months for patients who received lenvatinib and 3.7 months for patients who received sorafenib (HR, 0.66; 95% CI, 0.57–0.77).
Treatment-related adverse events were similar between the lenvatinib arm and the sorafenib arm.
An international, open-label, phase III, noninferiority trial (E7080-G000-304 [NCT01761266]) that included patients from 20 countries in Asia, Europe, and North America enrolled 954 patients with advanced HCC and Child-Pugh class A disease. Patients were randomly assigned in a 1:1 ratio to receive either lenvatinib (12 mg qd for body weight >60 kg or 8 mg for body weight <60 kg) or sorafenib (400 mg bid in 28-day cycles).[14] Patients with more than 50% liver involvement and portal vein invasion were excluded. › Treatment-related adverse events were similar between the lenvatinib arm and the sorafenib arm.
In the lenvatinib arm, the most common side effects were hypertension (any grade, 42%), diarrhea (39%), decreased appetite (34%), and decreased weight (31%), with 11 treatment-related deaths (hepatic failure, hemorrhage, and respiratory failure).
In the sorafenib arm, the most common side effects were palmar-plantar erythrodysesthesia (any grade, 52%), diarrhea (46%), hypertension (30%), and decreased appetite (27%), with four treatment-related deaths (hemorrhage, stroke, respiratory failure, and sudden death).
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (sorafenib):
The SHARP trial (NCT00105443) randomly assigned 602 patients with advanced HCC to receive either sorafenib 400 mg twice daily or a placebo. All but 20 of the patients had a Child-Pugh class A liver disease score; 13% were women.[15]
The SHARP trial (NCT00105443) randomly assigned 602 patients with advanced HCC to receive either sorafenib 400 mg twice daily or a placebo. All but 20 of the patients had a Child-Pugh class A liver disease score; 13% were women.[15]
The study was stopped at the second planned interim analysis, after 321 deaths. The median survival was significantly longer in the sorafenib group than the placebo group (10.7 months vs. 7.9 months; HR favoring sorafenib, 0.69; 95% CI, 0.55–0.87; P < .001).
A subsequent, similar trial was conducted in 23 centers in China, South Korea, and Taiwan. The study included 226 patients (97% with Child-Pugh class A liver function), and twice as many patients were randomly assigned to sorafenib than to placebo.[16]
Sources: 16
A subsequent, similar trial was conducted in 23 centers in China, South Korea, and Taiwan. The study included 226 patients (97% with Child-Pugh class A liver function), and twice as many patients were randomly assigned to sorafenib than to placebo.[16]
The median OS was 6.5 months for the sorafenib group versus 4.2 months for the placebo group (HR, 0.68; 95% CI, 0.50–0.93; P = .014).
Adverse events attributed to sorafenib in both of these trials included hand-foot skin reaction and diarrhea.[15,16]
Studies are also ongoing to evaluate the role of sorafenib after TACE, with chemotherapy, or in the presence of more-advanced liver disease.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
TKIs (regorafenib, cabozantinib, and ramucirumab) and immune checkpoint inhibitors (pembrolizumab and combination nivolumab with ipilimumab) are approved for the second-line treatment of patients with advanced HCC who have progressed while receiving sorafenib. However, the most effective second-line treatment after first-line combination atezolizumab and bevacizumab has not been determined. Physicians may consider other therapies approved in the first line (e.g., lenvatinib after atezolizumab and bevacizumab or immune checkpoint inhibitors).
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (regorafenib):
An international, double-blind, placebo-controlled, phase III trial (RESORCE [NCT01774344]) included patients from 21 countries in Asia, Europe, North America, South America, and Australia. The trial enrolled 573 patients with advanced HCC and Child-Pugh class A disease who had tolerated sorafenib but had disease progression. Patients were randomly assigned in a 2:1 ratio to receive either regorafenib (160 mg/day on days 1–21 of a 28-day cycle) or placebo.[17]
An international, double-blind, placebo-controlled, phase III trial (RESORCE [NCT01774344]) included patients from 21 countries in Asia, Europe, North America, South America, and Australia. The trial enrolled 573 patients with advanced HCC and Child-Pugh class A disease who had tolerated sorafenib but had disease progression. Patients were randomly assigned in a 2:1 ratio to receive either regorafenib (160 mg/day on days 1–21 of a 28-day cycle) or placebo.[17]
The median OS was 10.6 months for patients who received regorafenib and 7.8 months for patients who received a placebo (HR, 0.63; 95% CI, 0.50–0.79).[17][Level of evidence A1]
Sources: 17 · Level of evidence A1
The median PFS was 3.1 months for patients who received regorafenib and 1.5 months for patients who received placebo.
The most common grade 3 and 4 regorafenib-related side effects were hypertension (15%), hand-foot syndrome (13%), fatigue (9%), and diarrhea (3%).
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (cabozantinib):
An international, double-blind, placebo-controlled, phase III trial (CELESTIAL [NCT01908426]) that enrolled patients from 19 countries in Asia, Europe, North America, Australia, and New Zealand included 707 patients with advanced HCC and Child-Pugh class A disease. Patients had previously received sorafenib and progressed on at least one previous systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either cabozantinib (60 mg/day) or matching placebo. The primary end point was median OS.[18]
An international, double-blind, placebo-controlled, phase III trial (CELESTIAL [NCT01908426]) that enrolled patients from 19 countries in Asia, Europe, North America, Australia, and New Zealand included 707 patients with advanced HCC and Child-Pugh class A disease. Patients had previously received sorafenib and progressed on at least one previous systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either cabozantinib (60 mg/day) or matching placebo. The primary end point was median OS.[18]
The median OS was 10.2 months for patients who received cabozantinib and 8.0 months for patients who received placebo (HR, 0.76; 95% CI, 0.63–0.92, P = .005).[18][Level of evidence A1]
Sources: 18 · Level of evidence A1
The median PFS was 1.9 months for patients who received placebo and 5.2 months for patients who received cabozantinib (HR, 0.44; 95% CI, 0.36–0.52, P < .001).
Grade 3 or 4 side effects occurred in 68% of patients who received cabozantinib compared with 37% who received placebo. Common grade 3 or 4 side effects of cabozantinib included hand-foot syndrome (17%), hypertension (16%), abnormal aspartate aminotransferase level (12%), diarrhea (11%), and fatigue (10%).
While these findings are statistically significant for OS and PFS, the absolute improvement to OS was small, toxicity (including financial toxicity) was high, and the quality-of-life data are lacking to help guide selection of regimen and who should receive treatment. These factors should all be considered and individualized for each patient.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Ramucirumab is only used in patients with alpha-fetoprotein (AFP) levels of 400 ng/mL or higher.
Evidence (ramucirumab):
The REACH trial (NCT01140347) randomly assigned 565 patients with advanced HCC to receive either ramucirumab or placebo after first-line sorafenib. The primary end point was OS.[19][Level of evidence A1]
Sources: REACH · 19 · Level of evidence A1
The REACH trial (NCT01140347) randomly assigned 565 patients with advanced HCC to receive either ramucirumab or placebo after first-line sorafenib. The primary end point was OS.[19][Level of evidence A1]
The OS benefit was not statistically significant (9.2 months [95% CI, 8.0–10.6] in the ramucirumab arm and 7.6 months [95% CI, 6.0–9.3] in the placebo arm).
An unplanned subgroup analysis showed that patients with an AFP response had improved survival compared with patients who did not.
The REACH-2 trial (NCT02435433) included 292 patients with an Eastern Cooperative Oncology Group performance status of 0 or 1, an AFP level of at least 400 ng/mL, and Child-Pugh class A liver disease who had previously received sorafenib. Patients were randomly assigned to receive either ramucirumab or placebo.[20,21][Level of evidence A1]
Sources: REACH-2 · 20 · 21 · Level of evidence A1
The REACH-2 trial (NCT02435433) included 292 patients with an Eastern Cooperative Oncology Group performance status of 0 or 1, an AFP level of at least 400 ng/mL, and Child-Pugh class A liver disease who had previously received sorafenib. Patients were randomly assigned to receive either ramucirumab or placebo.[20,21][Level of evidence A1]
OS and PFS were improved in patients who received ramucirumab. The median OS was 8.5 months (95% CI, 7.0–10.6) for patients who received ramucirumab and 7.3 months (95% CI, 5.4–9.1) for patients who received placebo (HR, 0.710; 95% CI, 0.531–0.949; P = .0199).
A pooled analysis of the patients in the REACH trial with an AFP greater than 400 ng/mL and the patients in REACH-2 showed improved survival regardless of Barcelona Clinic Liver Cancer (BCLC) stage.[22][Level of evidence C1]
Sources: 22 · Level of evidence C1
A pooled analysis of the patients in the REACH trial with an AFP greater than 400 ng/mL and the patients in REACH-2 showed improved survival regardless of Barcelona Clinic Liver Cancer (BCLC) stage.[22][Level of evidence C1]
Among patients with BCLC stage B disease, the median OS was 13.7 months for the ramucirumab group and 8.2 months for the placebo group (HR, 0.43; 95% CI, 0.23–0.83). Among patients with BCLC stage C disease, the median OS was 7.7 months for the ramucirumab group and 4.8 months for the placebo group (HR, 0.72; 95% CI, 0.59–0.89).
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (pembrolizumab):
In an international, phase II, open-label, single-arm study (KEYNOTE-224 [NCT02702414]), 104 patients with BCLC stage B or C disease were enrolled across Europe, North America, and Japan. Patients had advanced HCC refractory to, or intolerant of, sorafenib and received pembrolizumab (200 mg IV every 3 weeks).[23]
Sources: KEYNOTE-224 · 23
In an international, phase II, open-label, single-arm study (KEYNOTE-224 [NCT02702414]), 104 patients with BCLC stage B or C disease were enrolled across Europe, North America, and Japan. Patients had advanced HCC refractory to, or intolerant of, sorafenib and received pembrolizumab (200 mg IV every 3 weeks).[23]
The objective response rate was 18.3% (95% CI, 11.4%–27.1%), and the median duration of response was 21.0 months (range, 3.1–39.5+).[23,24]
The median OS was 13.2 months (95% CI, 9.7–15.3).
The phase III KEYNOTE-394 study (NCT03062358) included 453 patients in Asia with advanced HCC previously treated with sorafenib or oxaliplatin-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either pembrolizumab (200 mg IV) or placebo every 3 weeks for up to 35 cycles.[25]
Sources: KEYNOTE-394 · 25
The phase III KEYNOTE-394 study (NCT03062358) included 453 patients in Asia with advanced HCC previously treated with sorafenib or oxaliplatin-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either pembrolizumab (200 mg IV) or placebo every 3 weeks for up to 35 cycles.[25]
The OS was 14.6 months (95% CI, 12.6–18.0) in the pembrolizumab arm and 13.0 months (95% CI, 10.5–15.1) in the placebo arm (HR, 0.79; 95% CI, 0.63–0.99; P = .0180). Notably, the 24-month OS rate was 34.3% in the pembrolizumab arm and 24.9% in the placebo arm.[25][Level of evidence A1]
Sources: 25 · Level of evidence A1
Grade 3 or higher treatment-related adverse events occurred in 14.4% of patients in the pembrolizumab arm and 5.9% of patients in the placebo arm.
Based on these data, the FDA granted accelerated approval for pembrolizumab in patients with advanced HCC previously treated with sorafenib.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (nivolumab and ipilimumab):
Cohort 4 of CheckMate 040 (NCT01658878), a multicenter, open-label, phase I/II study, enrolled 148 patients with advanced HCC and Child-Pugh class A liver function previously treated with sorafenib. Patients were randomly assigned in a 1:1:1 ratio to one of the following three dosages:[26]
Sources: CheckMate 040 · 26
Cohort 4 of CheckMate 040 (NCT01658878), a multicenter, open-label, phase I/II study, enrolled 148 patients with advanced HCC and Child-Pugh class A liver function previously treated with sorafenib. Patients were randomly assigned in a 1:1:1 ratio to one of the following three dosages:[26]
Arm A: Nivolumab 1 mg/kg with ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by maintenance nivolumab 240 mg every 2 weeks.
Arm B: Nivolumab 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for 4 doses, followed by maintenance nivolumab 240 mg every 2 weeks.
Arm C: Nivolumab 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks.
The median OS was 22.8 months (95% CI, 9.4–not reached) in arm A, 12.5 months (95% CI, 7.6–16.4) in arm B, and 12.7 months (95% CI, 7.4–33.0) in arm C.[26][Level of evidence A1]
Sources: 26 · Level of evidence A1
The objective response rates were 32% (95% CI, 20%–47%) in arm A, 27% (95% CI, 15%–41%) in arm B, and 29% (95% CI, 17%–43%) in arm C.
Grade 3 or higher treatment-related adverse events occurred in 76% of patients in arm A, 65% of patients in arm B, and 69% of patients in arm C.
Based on these data, the FDA granted accelerated approval for nivolumab (1 mg/kg IV) with ipilimumab (3 mg/kg IV every 3 weeks for 4 doses), followed by nivolumab (240 mg IV every 2 weeks) for patients with advanced HCC previously treated with sorafenib.[27]
Sources: 27
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Evidence (nivolumab):
A phase I/II, open-label, single-arm, dose-escalation and dose-expansion trial (CheckMate 040 [NCT01658878]) included 262 patients with advanced HCC and well-compensated liver function. Of those patients, 48 were enrolled in the dose-escalation phase and 214 patients were enrolled in the dose-expansion phase with nivolumab 3 mg/kg. Patients were treated with nivolumab every 2 weeks.[28] Cohorts included patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, uninfected patients with sorafenib-naïve disease, and uninfected patients with sorafenib-refractory disease.
Sources: CheckMate 040 · 28
A phase I/II, open-label, single-arm, dose-escalation and dose-expansion trial (CheckMate 040 [NCT01658878]) included 262 patients with advanced HCC and well-compensated liver function. Of those patients, 48 were enrolled in the dose-escalation phase and 214 patients were enrolled in the dose-expansion phase with nivolumab 3 mg/kg. Patients were treated with nivolumab every 2 weeks.[28] Cohorts included patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, uninfected patients with sorafenib-naïve disease, and uninfected patients with sorafenib-refractory disease.
The total overall objective response rate in the dose-expansion phase was 20% (95% CI, 15%–26%) with three complete responses. Results were similar in untreated, refractory, and HBV/HCV-infected patients.[28][Level of evidence B4]
Sources: 28 · Level of evidence B4
However, based on postmarketing requirements showing lack of confirmatory benefit, the indication for nivolumab monotherapy in the second-line setting was withdrawn in 2021.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Several phase II studies have suggested a benefit of radiation therapy in local control and OS compared with historical controls for patients with locally advanced HCC unsuitable for standard locoregional therapies.[29,30][Level of evidence C2]
Sources: 29 · 30 · Level of evidence C2
Curative-intent stereotactic body radiation therapy (SBRT) improved OS in a group of patients with HCC in the NRG/RTOG 1112 study (NCT01730937), which has been presented in abstract form. Most studies have included patients with Child-Pugh class A cirrhosis. Patients with Child-Pugh class B and C cirrhosis can also be treated with liver radiation, although with a higher risk of toxicity.[31][Level of evidence B1]
Sources: NRG/RTOG 1112 · 31 · Level of evidence B1
Many centers deliver photon-based SBRT, while others also offer proton-based (or other heavy-ion based) radiation therapy to the liver. Based on retrospective data, proton-based radiation therapy has the potential to offer a lower dose to the normal liver and dose-escalation to the liver tumor.[32,33] Clinical trials, including NRG-GI003 (NCT03186898), are evaluating whether photon or proton therapy is superior for patients with HCC.
Palliative radiation therapy improved pain response in a randomized trial presented in abstract form. Doses commonly used included 30 Gy in ten fractions and 8 Gy in one fraction. For more information, see the Radiation therapy section in Treatment of Localized Primary Liver Cancer.[34][Level of evidence B3]
Sources: Radiation therapy · 34 · Level of evidence B3
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
There is no evidence supporting a survival benefit for patients with advanced HCC receiving systemic cytotoxic chemotherapy when compared with no treatment or best supportive care.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025. Captured 2026-09-09.
Intrahepatic recurrence is the most common pattern of failure after curative treatment.[1] Intrahepatic recurrence of hepatocellular carcinoma (HCC) may be the result of either intrahepatic metastasis or metachronous de novo tumor. Theoretically, intrahepatic metastasis may be associated with less favorable outcomes because it is most likely the result of concurrent hematogenous metastases. However, in clinical practice, the two causes of recurrence cannot be differentiated.
Sources: 1
Treatment options for patients with recurrent primary liver cancer with liver-limited disease without vascular involvement include:
Liver transplant.
Surgical resection.
Ablation.
Radiation therapy.
Evidence (curative radiation therapy):
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
Sources: NCT04047173 · 2
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
The local PFS rate was better with SBRT than RFA (hazard ratio [HR], 0.45, 95% confidence interval [CI], 0.24–0.87; P = .04). The 2-year local PFS rates were 92.7% (95% CI, 87.3%–98.5%) with SBRT and 75.8% (95% CI, 67.2%–85.7%) with RFA.[2][Level of evidence B1]
Sources: 2 · Level of evidence B1
There was no statistically significant difference in the 2-year OS rate between the two groups, at 97.6% (95% CI, 94.3%–100.0%) for SBRT and 93.9% (95% CI, 88.9%–99.2%) for RFA (HR, 0.91; 95% CI, 0.37–2.22; P = .830).
The rate of adverse events was not different between the two groups.
Treatment options for patients with recurrent primary liver cancer with extrahepatic disease or vascular involvement include:
Palliative therapy (transcatheter arterial chemoembolization [TACE] and systemic therapy).
Regarding primary HCC, the treatment strategy for recurrent intrahepatic HCC is determined by the function of the liver and the macroscopic tumor features (e.g., number of lesions, site of recurrence, and invasion of major vessels). Using the same selection criteria that are used for primary HCC, either curative (i.e., salvage liver transplant, surgical resection, and ablation) or palliative treatments (e.g., TACE and sorafenib) can be offered for recurrent HCC.
Evidence (salvage liver transplant, resection, and ablation):
In a retrospective study of 183 patients with intrahepatic recurrence, only 87 of the patients could be treated with curative intent (transplant, resection, and ablation).[3][Level of evidence A2]
Sources: 3 · Level of evidence A2
In a retrospective study of 183 patients with intrahepatic recurrence, only 87 of the patients could be treated with curative intent (transplant, resection, and ablation).[3][Level of evidence A2]
The 5-year tumor-free survival rate was 57.9% for liver transplant, 49.3% for resection, and 10.6% for radiofrequency ablation. Subgroup analysis showed that transplant and resection led to comparable survival and that both treatments led to significantly better outcomes than did ablation (P < .001). However, selection bias was a major pitfall of this retrospective study.
Other than the use of ablation for secondary treatment, risk factors for shorter disease-free survival were identified as alpha-fetoprotein blood levels above 400 ng/mL and recurrence within 1 year of treatment (47.5% vs. 6.7% at 5 years, P < .001).
Other studies have also suggested that most of the recurrences that appear early during follow-up are caused by tumor dissemination and have a more aggressive biological pattern than primary tumors.[4,5]
Clinical trials are appropriate and can be offered to patients with recurrent HCC whenever possible.
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Surveillance is used for lesions smaller than 1 centimeter found during screening. Follow-up every 3 months is common. Surveillance is closely watching a person's condition but not giving any treatment unless there are changes in test results that show the condition is getting worse. During active surveillance, certain exams and tests are done on a regular schedule.
Sources: lesions
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
A partial hepatectomy (surgery to remove the part of the liver where cancer is found) may be done. A wedge of tissue, an entire lobe, or a larger part of the liver, along with some of the healthy tissue around it is removed. The remaining liver tissue takes over the functions of the liver and may regrow.
Sources: lobe
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
In a liver transplant, the entire liver is removed and replaced with a healthy donated liver. A liver transplant may be done when the disease is in the liver only and a donated liver can be found. If the person has to wait for a donated liver, other treatment is given as needed.
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Ablation therapy removes or destroys tissue. Different types of ablation therapy are used for liver cancer:
Radiofrequency ablation: Special needles are inserted directly through the skin or through an incision in the abdomen to reach the tumor. High-energy radio waves heat the needles and tumor which kills cancer cells.
Sources: incision · abdomen · tumor · radio waves
Microwave therapy: The tumor is exposed to high temperatures created by microwaves. This can damage and kill cancer cells or make them more sensitive to the effects of radiation and certain anticancer drugs.
Percutaneous ethanol injection: A small needle is used to inject ethanol (pure alcohol) directly into a tumor to kill cancer cells. Several treatments may be needed. Usually local anesthesia is used, but if the person has many tumors in the liver, general anesthesia may be used.
Sources: anesthesia
Cryoablation: An instrument is used to freeze and destroy cancer cells. This type of treatment is also called cryotherapy and cryosurgery. The doctor may use ultrasound to guide the instrument. Learn more at Cryosurgery to Treat Cancer.
Sources: Cryoablation · ultrasound · Cryosurgery to Treat Cancer
Electroporation therapy: Electrical pulses are sent through an electrode placed in a tumor to kill cancer cells. Electroporation therapy is being studied in clinical trials.
Sources: electrode
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Embolization therapy is used for people who cannot have surgery to remove the tumor or ablation therapy and whose tumor has not spread outside the liver. Embolization therapy is the use of substances to block or decrease the flow of blood through the hepatic artery to the tumor. When the tumor does not get the oxygen and nutrients it needs, it will not continue to grow.
Sources: hepatic artery
The liver receives blood from the hepatic portal vein and the hepatic artery. Blood that comes into the liver from the hepatic portal vein usually goes to the healthy liver tissue. Blood that comes from the hepatic artery usually goes to the tumor. When the hepatic artery is blocked during embolization therapy, the healthy liver tissue continues to receive blood from the hepatic portal vein.
Sources: hepatic portal vein
There are two main types of embolization therapy:
Transarterial embolization (TAE): A small incision (cut) is made in the inner thigh and a catheter (thin, flexible tube) is inserted and threaded up into the hepatic artery. Once the catheter is in place, a substance that blocks the hepatic artery and stops blood flow to the tumor is injected.
Transarterial chemoembolization (TACE): This procedure is like TAE except an anticancer drug is also given. The procedure can be done by attaching the anticancer drug to small beads that are injected into the hepatic artery or by injecting the anticancer drug through the catheter into the hepatic artery and then injecting the substance to block the hepatic artery. Most of the anticancer drug is trapped near the tumor and only a small amount of the drug reaches other parts of the body. This type of treatment is also called chemoembolization.
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies used to treat advanced liver cancer include:
bevacizumab
Sources: bevacizumab
cabozantinib
Sources: cabozantinib
lenvatinib
Sources: lenvatinib
ramucirumab
Sources: ramucirumab
regorafenib
Sources: regorafenib
sorafenib
Sources: sorafenib
Learn more about targeted therapy and its side effects at Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the person's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: immune system
Immune checkpoint inhibitors are a type of immunotherapy. Immune checkpoint inhibitors that may be used to treat liver cancer include:
Sources: Immune checkpoint inhibitors
atezolizumab with the targeted therapy drug bevacizumab or cabozantinib
Sources: atezolizumab
durvalumab with tremelimumab
Sources: durvalumab · tremelimumab
nivolumab with ipilimumab
Sources: nivolumab · ipilimumab
pembrolizumab
Sources: pembrolizumab
Learn more about immunotherapy and its side effects at Immunotherapy to Treat Cancer and Immunotherapy Side Effects.
Sources: Immunotherapy to Treat Cancer · Immunotherapy Side Effects
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
External radiation therapy uses a machine outside the body to send high-energy x-rays or other types of radiation toward the area of the body with cancer. Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective. The number of treatments is based on details about the cancer, such as the size and location of the tumor. Certain ways of giving external radiation therapy can help keep radiation from damaging nearby healthy tissue:
Conformal radiation therapy: Conformal radiation therapy uses a computer to make a 3-dimensional, or 3-D, picture of the tumor and shapes the radiation beams to fit the tumor. This allows a high dose of radiation to reach the tumor and causes less damage to nearby healthy tissue.
Stereotactic body radiation therapy: Stereotactic body radiation therapy uses special equipment to place the person in the same position for each radiation treatment. Once a day for several days, a radiation machine aims a larger than usual dose of radiation directly at the tumor. By having the person in the same position for each treatment, there is less damage to nearby healthy tissue. This procedure is also called stereotactic external beam radiation therapy and stereotaxic radiation therapy.
Proton beam radiation therapy: Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor.
Learn more about radiation therapy and its side effects at Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.
Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Treatment of localized liver cancer may include:
Sources: localized
surveillance for lesions smaller than 1 centimeter
partial hepatectomy (surgery to remove the part of the liver where cancer is found)
liver transplant
ablation of the tumor using:
ablation of the tumor using:
radiofrequency ablation
microwave therapy
percutaneous ethanol injection
cryoablation
radiation therapy
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Treatment of locally advanced or metastatic liver cancer may include:
Sources: locally advanced · metastatic
transarterial embolization (TAE) or transarterial chemoembolization (TACE) in people with locally advanced liver cancer
bevacizumab, cabozantinib, lenvatinib, ramucirumab, regorafenib, or sorafenib
atezolizumab with bevacizumab or cabozantinib, durvalumab with tremelimumab, nivolumab with ipilimumab, or pembrolizumab
radiation therapy
Source: Liver Cancer Treatment, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Treatment options for recurrent primary liver cancer may include:
Sources: recurrent
total hepatectomy (surgery to remove all of the liver) and liver transplant
partial hepatectomy (surgery to remove the part of the liver where cancer is found)
ablation therapy
radiation therapy
transarterial chemoembolization (TACE) and sorafenib as palliative therapy to relieve symptoms and improve quality of life
Sources: palliative therapy
Carcinoma, Hepatocellular
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
ClinicalTrials.gov recordHepatocellular Carcinoma (HCC)
ClinicalTrials.gov recordCarcinoma, Hepatocellular
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma, Liver Metastases
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordCarcinoma, Hepatocellular
ClinicalTrials.gov recordRecurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordCarcinoma, Hepatocellular
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordHepatocellular Carcinoma
ClinicalTrials.gov recordAdvanced Hepatocellular Carcinoma
Treatment of Localized Primary Liver Cancer
Treatment of Locally Advanced or Metastatic Primary Liver Cancer
Primary Liver Cancer
Treatment of Recurrent Primary Liver Cancer
Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular...
DailyMed label